MoneyWorks4Me

NATCO Pharma informs about disclosure

09 Nov 2022 Evaluate

NATCO Pharma has informed that it enclosed the disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding ‘NATCO Announces Launch of First Generic Version of Pomalyst® (Pomalidomide) Capsules in the Australian Market’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1743.00
Dr. Reddys Labs. 1224.50
Cipla 1337.00
Lupin 1925.00
Zydus Lifesciences 1127.85
View more..